Buckingham Capital Management, Inc. Biogen Inc. Transaction History

Buckingham Capital Management, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 07, 2019	SELL	$216.71 - $338.96 $843,218 - $1.32 Million	-3,891 Closed	0 $0
Q4 2018 Feb 04, 2019	SELL	$278.5 - $352.75 $8,912 - $11,288	-32 Reduced 0.82%	3,891 $1.17 Million
Q3 2018 Nov 20, 2018	BUY	$293.51 - $383.83 $7,924 - $10,363	27 Added 0.69%	3,923 $1.39 Million
Q2 2018 Aug 10, 2018	SELL	$257.52 - $306.91 $7,725 - $9,207	-30 Reduced 0.76%	3,896 $1.13 Million
Q1 2018 May 11, 2018	BUY	$260.13 - $367.91 $221,890 - $313,827	853 Added 27.76%	3,926 $1.08 Million
Q4 2017 Feb 13, 2018	BUY	$307.64 - $344.58 $107,674 - $120,603	350 Added 12.85%	3,073 $979,000
Q3 2017 Nov 07, 2017	BUY	$281.15 - $329.69 $89,405 - $104,841	318 Added 13.22%	2,723 $853,000
Q2 2017 Aug 10, 2017	BUY	N/A	2,405	2,405 $653,000

1,015

126M

1.12M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $20.3B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Buckingham Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Buckingham Capital Management, Inc. with notifications on news.